What the Hearing Is and Why It Matters

First, the short version

The FDA has an advisory committee called the PCAC. On July 23 and 24, 2026, it meets to consider whether certain peptides stay eligible to be compounded for patients who have a valid prescription. The committee reviews the evidence and votes on a recommendation. The FDA then decides what to do with that recommendation. A vote is a recommendation, not a final rule.

The FDA has opened a public comment period before the meeting. Anyone affected can submit a comment, and comments filed by July 9, 2026 are provided directly to the committee.

That is the whole thing. The rest of this page fills in what each piece means.

What the PCAC is

PCAC stands for the Pharmacy Compounding Advisory Committee. It is an advisory body to the FDA. Its job is to look at the science and advise the agency on which substances are appropriate for pharmacists to compound. It is made up of experts who review evidence in public and make recommendations.

The key word is advisory. The committee does not write regulations on its own. It studies a question, hears from the public, and hands the FDA a recommendation. The FDA makes the final call.

What compounding is

Compounding is when a licensed pharmacist prepares a medication for a specific patient rather than dispensing a mass-produced product off the shelf. A pharmacist might compound a medication because a patient needs a different dose, cannot tolerate an ingredient in the standard version, or needs a form that is not commercially available.

Compounding is a long-established, regulated part of pharmacy. Two kinds of facilities do it under federal and state oversight:

• 503A pharmacies prepare compounded medications for individual patients based on a prescription. They are regulated by state boards of pharmacy.
• 503B outsourcing facilities make compounded medications in larger batches and register with the FDA, which inspects them. They are held to stricter manufacturing standards.

Both are inspected and standards-bound. None of those standards apply to the unregulated gray-market vendors that sell peptides online with no oversight. That distinction, accredited and supervised versus unregulated and self-sourced, is at the heart of the safety conversation.

What is actually being decided on July 23 and 24

The committee is considering whether licensed pharmacies can prepare certain peptide therapies for patients who have a valid prescription. In practical terms, that affects whether a patient who is prescribed one of these therapies can get it prepared by an accredited pharmacy, or whether that regulated path narrows.

It is worth being precise about what this is and is not. It is about access through a regulated, supervised pathway: whether a licensed pharmacy can prepare these therapies for a patient on a prescription. It is not a vote to remove oversight, and it is not the same as the FDA approving these as brand-name drugs. The real question is simply which channel patients are left with: a regulated pharmacy, or the unregulated gray market.

The 2023 backdrop, framed honestly

To understand why this matters now, it helps to know the recent history. In 2023, a compounding-eligibility decision under regulatory review restricted a set of peptides from being compounded. The therapies did not disappear. Instead, many patients who relied on them were pushed toward an unregulated gray market: online vendors and products labeled “for research use only,” with no inspection, no verified quality, and no clinical supervision.

That is the honest framing, and it is an important one. This is not a story about a ban. It is a story about access moving out of regulated, accountable channels and into a market with no rules at all. The current review is a chance to correct that.

Why it matters, by stakeholder

• Patients with chronic conditions. For many people, this is about a therapy that is helping them, and whether they can get it safely and legally from a regulated pharmacy instead of taking their chances in the gray market. This is not about a shortcut for the gym. It is about chronic-disease patients and the clinician-patient decision.
• Compounding pharmacists. Accredited 503A and 503B pharmacies are inspected and held to standards for sterility, potency, and quality. The hearing affects their ability to prepare these medications for the patients who are prescribed them, and to do it within the regulated system they already answer to.
• Clinicians. Prescribers want evidence, safety, and a regulated supply they can trust. The outcome shapes whether they can keep care inside accountable channels, with quality-controlled product and proper oversight, rather than watching patients self-source.

Where AAPM stands

The American Academy of Peptide Medicine is pro-access and pro-safety at the same time. Our position is to protect and restore safe, regulated access to peptide therapies. The fix for the gray market is rigor and supervision, not prohibition, and not deregulation either.

AAPM is a self-regulatory body working with regulators and industry to set quality standards, so that physicians and pharmacists have a safe, quality, and regulated pathway to care for their patients. We are the honest broker between an unregulated gray market and outright prohibition: protect access, insist on quality and supervision, and build the standards that make a safe, regulated pathway real.

The real question before the hearing is this: does the current rule make patients safer, or does it hand them to a market with no rules at all?

A vote is a recommendation, not a rule

It is worth repeating, because it sets the right expectation. The PCAC votes on a recommendation. The FDA then decides what to do with it. The committee’s job is to advise, and one of the things it weighs is the public record. That record is built from comments like yours.

How to take part

• Read the basics first if you have not: Peptides and Safe Access, Explained for Everyone.
• Watch the hearing live. Sign up and we will send you the link when the FDA stream begins. (Take part)
• Submit a public comment to the FDA on regulations.gov. It becomes part of the public record. Comments filed by July 9, 2026 are provided directly to the committee, so early carries more weight. (Take part)